Biopharma rivals at Roche and Bayer both stand to benefit from the trend toward increased testing of cancer patients
Loxo Oncology has been one of the pioneers in the move to develop new, tissue-agnostic cancer drugs. But the biggest challenge it faces won …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
